X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs SUVEN LIFE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA SUVEN LIFE ALEMBIC PHARMA/
SUVEN LIFE
 
P/E (TTM) x 27.0 18.6 145.3% View Chart
P/BV x 5.4 4.1 134.1% View Chart
Dividend Yield % 0.6 0.6 110.9%  

Financials

 ALEMBIC PHARMA   SUVEN LIFE
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-18
SUVEN LIFE
Mar-18
ALEMBIC PHARMA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs645251 257.2%   
Low Rs470155 303.1%   
Sales per share (Unadj.) Rs166.149.1 338.1%  
Earnings per share (Unadj.) Rs21.99.7 225.3%  
Cash flow per share (Unadj.) Rs27.511.4 241.3%  
Dividends per share (Unadj.) Rs4.001.50 266.7%  
Dividend yield (eoy) %0.70.7 97.1%  
Book value per share (Unadj.) Rs117.860.3 195.3%  
Shares outstanding (eoy) m188.52127.28 148.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.1 81.3%   
Avg P/E ratio x25.520.9 121.9%  
P/CF ratio (eoy) x20.317.8 113.8%  
Price / Book Value ratio x4.73.4 140.7%  
Dividend payout %18.315.4 118.3%   
Avg Mkt Cap Rs m105,09025,825 406.9%   
No. of employees `000NA1.1 0.0%   
Total wages/salary Rs m6,228613 1,016.5%   
Avg. sales/employee Rs ThNM5,832.6-  
Avg. wages/employee Rs ThNM571.5-  
Avg. net profit/employee Rs ThNM1,153.8-  
INCOME DATA
Net Sales Rs m31,3086,253 500.7%  
Other income Rs m70233 30.2%   
Total revenues Rs m31,3786,485 483.8%   
Gross profit Rs m6,4311,982 324.5%  
Depreciation Rs m1,055213 494.9%   
Interest Rs m3446 73.4%   
Profit before tax Rs m5,4131,955 276.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m-810-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,204718 167.6%   
Profit after tax Rs m4,1281,237 333.8%  
Gross profit margin %20.531.7 64.8%  
Effective tax rate %22.236.7 60.5%   
Net profit margin %13.219.8 66.7%  
BALANCE SHEET DATA
Current assets Rs m18,2475,622 324.6%   
Current liabilities Rs m11,2351,168 962.2%   
Net working cap to sales %22.471.2 31.4%  
Current ratio x1.64.8 33.7%  
Inventory Days Days8681 105.1%  
Debtors Days Days6136 170.8%  
Net fixed assets Rs m20,0353,325 602.6%   
Share capital Rs m377127 296.2%   
"Free" reserves Rs m21,8247,547 289.2%   
Net worth Rs m22,2017,674 289.3%   
Long term debt Rs m5,00014 35,971.2%   
Total assets Rs m39,4119,135 431.4%  
Interest coverage x160.243.2 370.6%   
Debt to equity ratio x0.20 12,433.8%  
Sales to assets ratio x0.80.7 116.1%   
Return on assets %10.614.0 75.2%  
Return on equity %18.616.1 115.4%  
Return on capital %19.726.0 75.8%  
Exports to sales %46.40-   
Imports to sales %10.50-   
Exports (fob) Rs m14,535NA-   
Imports (cif) Rs m3,288NA-   
Fx inflow Rs m14,7225,066 290.6%   
Fx outflow Rs m7,0262,001 351.1%   
Net fx Rs m7,6963,065 251.1%   
CASH FLOW
From Operations Rs m3,124699 446.7%  
From Investments Rs m-8,844-6 144,980.3%  
From Financial Activity Rs m5,026-577 -871.1%  
Net Cashflow Rs m-693116 -596.1%  

Share Holding

Indian Promoters % 74.1 63.4 116.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 0.0 -  
FIIs % 9.1 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 36.5 38.1%  
Shareholders   49,328 37,287 132.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   BIOCON LTD  CADILA HEALTHCARE  VENUS REMEDIES  PLETHICO PHARMA  WOCKHARDT LTD.  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Slumps Over 530 Points(Closing)

Share markets in India continued their sell-off seen during the last week and ended the day deep in the red. All sectoral indices traded on a negative note.

Related Views on News

SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Sep 24, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - SUN PHARMA COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS